Aripiprazole Tablet
Product Images NDC 71335-1687

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier curve comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo treatment groups. The x-axis shows the time in days, and the y-axis indicates the proportion relapsed. The number of subjects at risk is displayed below the x-axis for each group at various time points.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph comparing the proportion of subjects with relapse over 364 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. Aripiprazole is represented by a solid blue line, placebo by a dashed red line. The number of subjects at risk is listed below for each group at multiple time points.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A bar chart depicting the fold change and 90% confidence interval of dehydro-aripiprazole pharmacokinetics (AUC and Cmax) relative to a reference without interacting drug. It compares effects of CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam on these parameters.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A plot showing the fold change and 90% confidence intervals for pharmacokinetic parameters such as AUC and Cmax, and INR, for various drugs including dextromethorphan, warfarin (S- and R- forms), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (and its metabolite O-desmethylvenlafaxine), and escitalopram. The x-axis represents change relative to reference without interacting drug, ranging approximately from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic (PK) chart showing the fold change and 90% confidence intervals for Aripiprazole based on various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents the change relative to a reference value for AUC and Cmax parameters.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' compares pharmacokinetic variables (AUC and Cmax) under different conditions: CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, showing changes relative to a reference value.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart illustrating the fold change and 90% confidence interval for Aripiprazole AUC and Cmax when administered with various inhibitors, inducers, and other drugs. The x-axis shows the change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of Aripiprazole, the active ingredient in the oral tablet prescription drug Aripiprazole 20 mg by Bryant Ranch Prepack. The diagram shows the molecular framework including chlorine-substituted rings and heterocyclic components.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A line graph showing the proportion of subjects with relapse over days from randomization for Aripiprazole and Placebo groups. The x-axis represents days from randomization up to 182 days, with the number of subjects at risk listed below. The y-axis shows the proportion with relapse, ranging from 0 to 1. Aripiprazole is indicated by a solid blue line showing a lower relapse proportion, and Placebo by a dashed red line showing a higher relapse proportion.*

FDA Label Image

Label Image (Lbl713351687)

Label for Aripiprazole 20 mg oral tablets, packaged by Bryant Ranch Prepack in Burbank, CA, with a quantity of 30 tablets. The label states to compare to Abilify 20 mg tablets by Alkem Laboratories Limited. It includes storage instructions to keep at room temperature 20°-25°C and to keep out of reach of children. The label shows the NDC 71335-1687-1 and a lot number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.